普乐可复对大鼠小肠移植排斥反应的免疫抑制作用.doc

普乐可复对大鼠小肠移植排斥反应的免疫抑制作用
作者:李纪鹏王为忠施海李孟彬
【关键词】小肠移植
关键词: 小肠移植;他罗利姆;移植物排斥;免疫抑制

摘要:目的观察大鼠小肠移植术后应用普乐可复(FK506)对小肠移植排斥反应的免疫抑制作用. 方法选用近交系大鼠F344/N(RTⅠ1 )和Wistar大鼠进行全小肠异位移植,,异基因移植组F344/N-Wistar;第2组,小剂量普乐可复治疗组F344/N-Wistar+FK506(・kg-1 ・d-1 ,0~14d,im);第3组,普乐可复治疗组F344/N-Wistar+FK506(・kg-1 ・d-1 ,0~14d,im);第4组,同基因移植组(F344/N-F344/N).观察大鼠的一般状况及存活时间并于术后第3,5,7日取移植小肠标本进行病理学检查和比较. 结果第1组大鼠存活时间与其他3组有显著差异(P<),第1组大鼠在术后第3,5,7日病理学检查移植肠出现排斥反应,而第2,3,4组无明显排斥,可长期存活. 结论普乐可复能明显抑制小肠移植急性排斥反应的产生,显著地延长移植物存活时间.

Keywords:small bowel transplantation;tacrolimus;trans-plant rejection;immunosuppression

Abstract:AIM To observe the immunosuppression of FK506on the transplant rejection after small bowel trans-plantation in Heterotopic small bowel transplants was carried out between inbred F344/N and Wis-tar recipients were divided into four groups,groupⅠ,F344/N-wistar;groupⅡ,F344/N-wistar+FK506(・kg-1 ・d-1 ,0~14d,im);groupⅢ,F344/N-wistar+FK506(・kg-1 ・d-1 ,0~14d,im);groupIV,F344/N-F344/ transplant clinical course and survial dura-tion were recorded and the grafts were harvested on post-op-erative day3,5, samples were examined pathological-ly pared with each The survial duration of groupⅠwas significantly different from that of the other tree pathological examination of the transplantated bowel specimen from groupⅠshowed that the transplant rejection on post-operative day3,5and7while none of groupⅡ,ⅢandⅣhad pathological evidence of transplant FK506could obvi-ously suppress the transplant rejection in small bowel trans-plantation in rats and significantly prolong the survial dura-tion.

0 引言

小肠移植被视为治疗终末期肠功能衰竭的唯一确切的方法,而小肠属于高免疫原性器官,含有丰富的淋巴组织,与其他器官移植相比,小肠移植排斥反应尤为严重,也是小肠移植失败的主要原因[1] ,皮质类固醇激素,硫唑嘌呤,环孢霉素A等免疫抑制剂对于小肠移植排斥反应效果不理想,且本身具有较大的毒副作用,(FK506)是一种新型的免疫抑制药物,其免疫抑制作用较环孢霉素A强10~100倍[2] ,我们采用大鼠小肠移植动物模型,研究